Results of the Immunotherapy for Brain Tumor

RESULTS OF THE PHASE 1 MLC IMMUNOTHERAPY TRIAL 1996 – 1998

A “Phase 1″ study is performed to detect toxicity of a new experimental model. Of the 19 patients in the Phase I trial, there was no toxicity within a certain dose range of activated white blood cells, and 25% of the patients enrolled (1 patients with glioblastoma multiforme and 2 with anaplastic astrocytoma) are currently in complete remission with no evidence of active disease since their implantation in 1996.

3 Years Post Immunotherapy

Glioblastoma Multiforme (Grade 4 astrocytoma)
Before and 3 1/2 years post immunotherapy. Biopsies of the residual mass on the right showed only dead, necrotic tissue.

CURRENT TRIAL – HOAG MEMORIAL HOSPITAL PRESBYTERIAN

Malignant Brain Tumor Treatment Protocol
Current Trial
Hoag Memorial Hospital Presbyterian (Newport Beach, CA)
Christopher M. Duma, MD
Neurological Surgery, Gamma Knife Radiosurgery
Neurosurgical Oncology

The goal of the program is long-term survival, and attempts at a “cure” of perhaps one of the most difficult tumors to treat. This, in our opinion, is only possible using a combination of conventional therapies and various biological techniques. Surgery, radiation and chemotherapy alone are not the answer. Our protocol for a newly diagnosed brain tumor is as follows:

1A) Gross total (radiographically complete) tumor resection using specialized stereotactic neuronavigational techniques. It has been shown that when this is possible it markedly extends the patient’s chance of survival. Unfortunately it is not always possible for all tumors. Or,

1B) Stereotactic, MRI-guided biopsy (for tumors difficult to fully resect or tumors in eloquent locations in the brain).

2) Tissue from 1A and 1B above is sent for chemosensitivity assay and/or vaccine production.

3) Gamma Knife radiosurgery Boost to all abnormal tissue and if possible treatment of “the leading edge” of the tumor tracts (fingers) seen on post-operative scans. One day procedure. This alone has been shown to double the median survival. It is often directed by MR Spectroscopy, a technique which requires only a MRI scan, but the scan shows spectroscopic patterns which show live tumor molecules or dead tumor molecules.

4) Involved-field, conventional radiation therapy. (5-6 weeks) This has been shown to double life expectancy.

5) Chemotherapy. This is directed by the results of #2 above. The original tumor is grown in tissue culture and then exposed to different chemotherapy agents. Then selective sensitivity is then determined. In some cases tumor is only sensitive to certain agents and in others not at all. There is no sense in giving chemotherapy and compromising the immune system if the tumor will not respond.

6) IL-2 activated autologous lymphocytes. Our longest survivors had enrolled in this protocol. We have resumed this protocol at Hoag Memorial Hospital, and intend to use it in a series of 30 up-front patients. This means that only patients with newly diagnosed glioblasotomaglioblastoma multiforme are eligible. The lymphocyte portion of a peripheral blood draw is extracted and exposed to the cytokine IL-2 in vitro. This exposure activates the patients’ autologous cells over a 3-day incubation period. They are then implanted into the tumor bed after a thorough resection to debulk the residual/recurrent tumor.

7) Re-operation for a radiographically complete resection, possible implantation of Gliadel chemotherapy wafers, and return to step #2 above.

Of course any patient of the immunotherapy for brain tumor may enter the protocol at any point depending upon their previous treatment strategies.

We have been using the above protocols for all of our patients with anaplastic astrocytoma and glioblastoma multiforme and other malignant gliomas (oligodendrogliomas, mixed tumors, etc.) We are following some patients who have completed only up to step 3 since 1997 without a recurrence. Thus some of my patients are in complete remission with only the initial phases of this regimen.

Please send your films and a short history to my Orange County office in Newport Beach, California. We will enter you into our data base, present your films free of charge at our weekly Gamma Knife, multidisciplinary Tumor Board, and get back to you by telephone or by mail with our recommendations. Otherwise, preferentially, please make an appointment at my office to discuss these options in person.


If you wish to make a consultation appointment with Dr. Duma, or for further information regarding our immunotherapy results, please register on our website. Also, you can call us at 949-642-6787.

Improving
Quality of LifeRequest an appointment

Testimonials

'I was given a couple of months to live. Dr Duma is brilliant.'

Eric Muranaka
Malignant Brain Tumor
8 year survivor

'Thanks to Dr. Duma, my brain tumor has completely diminished.'

Victor Pimenta
Anaplastic Astrocytoma
14 year survivor

'He was knowledgeable and patient when addressing my concerns!'

Allison Smith-Conway
Parkinson's Disease
Symptom free 2 years

'I am alive today because of Dr. Duma.'

Lindsay Susskind
Glioblastoma Multiform
6 year survivor

'The standard of care Dr. Duma offers is stellar. '

Paul Roberts
Glioblastoma Multiform
6 year survivor

'You have extended my life, not only in time, but also the quality of life.'

Richard Teter
Glioblastoma Multiform
2 year survivor

'He is always concerned for my well-being. I trust him with my life!'

Kathy Hyams
Breast Cancer Brain Metastases
10 year survivor

Dr. Duma Patented Radio Surgery